연구

연구업적

최근 5년 연구업적 현황
연도 2020년 2019년 2018년 2017년 2016년 합계
발표논문 303편 311편 124편 125편 161편 1024편
2761. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Dae-Won Lee 1, Eun Ju Cho 1 2, Jeong-Hoon Lee 1 2, Su Jong Yu 1 2, Yoon Jun Kim 1 2, Jung-Hwan Yoon 1 2, Tae-Yong Kim 1 3, Sae-Won Han 1 3, Do-Youn Oh 1 3, Seock-Ah Im 1 3, Tae-You Kim 1 3, Youngeun Lee 4, Haeryoung Kim 4, Kyung-Hun Lee 5 3
Clin Cancer Res . 2020 Nov 2. Link
2760. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes 1, David W Cescon 2, Hope S Rugo 3, Zbigniew Nowecki 4, Seock-Ah Im 5, Mastura Md Yusof 6, Carlos Gallardo 7, Oleg Lipatov 8, Carlos H Barrios 9, Esther Holgado 10, Hiroji Iwata 11, Norikazu Masuda 12, Marco Torregroza Otero 13, Erhan Gokmen 14, Sherene Loi 15, Zifang Guo 16, Jing Zhao 16, Gursel Aktan 16, Vassiliki Karantza 16, Peter Schmid 17, KEYNOTE-355 Investigators
Lancet . 2020 Dec 5;396(10265):1817-1828. Link
2759. Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients
Mihong Choi 1 2, Jiyeon Han 3, Bo Ram Yang 3, Myoung-Jin Jang 3, Miso Kim 2 4, Dae-Won Lee 2, Tae-Yong Kim 2 4, Seock-Ah Im 2 4, Han-Byoel Lee 5, Hyeong-Gon Moon 5, Wonshik Han 5, Dong-Young Noh 5, Kyung-Hun Lee 2 4
Cancer Res Treat . 2020 Sep 23. Link
2758. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P Schmid 1, R Salgado 2, Y H Park 3, E Muñoz-Couselo 4, S B Kim 5, J Sohn 6, S-A Im 7, T Foukakis 8, S Kuemmel 9, R Dent 10, L Yin 11, A Wang 11, K Tryfonidis 11, V Karantza 11, J Cortés 12, S Loi 2
Ann Oncol . 2020 May;31(5):569-581. Link
2757. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens 1 , Francisco J Esteva 2 , Mark Beresford 3 , Cristina Saura 4 , Michelino De Laurentiis 5 , Sung-Bae Kim 6 , Seock-Ah Im 7 , Yifan Wang 8 , Roberto Salgado 9 , Aruna Mani 10 , Jigna Shah 10 , Chiara Lambertini 11 , Haiying Liu 10 , Sanne L de Haas 11 , Monika Patre 11 , Sherene Loi 12
Lancet Oncol . 2020 Oct;21(10):1283-1295. Link
2756. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
Stephen R D Johnston 1 , Roberto Hegg 2 , Seock-Ah Im 3 , In Hae Park 4 , Olga Burdaeva 5 , Galina Kurteva 6 , Michael F Press 7 , Sergei Tjulandin 8 , Hiroji Iwata 9 , Sergio D Simon 10 , Sarah Kenny 11 , Severine Sarp 11 , Miguel A Izquierdo 11 , Lisa S Williams 12 , William J Gradishar 13
J Clin Oncol . 2021 Jan 1;39(1):79-89. Link
2755. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
Ahrum Min 1 2 , Kwangsoo Kim 1 , Kyeonghun Jeong 1 , Seongmin Choi 1 , Seongyeong Kim 2 , Koung Jin Suh 2 3 , Kyung-Hun Lee 4 5 , Sun Kim 6 7 8 , Seock-Ah Im 9 10 11 12
Sci Rep . 2020 Jul 27;10(1):12506. Link
2754. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M Domchek 1 , Sophie Postel-Vinay 2 , Seock-Ah Im 3 , Yeon Hee Park 4 , Jean-Pierre Delord 5 , Antoine Italiano 6 , Jerome Alexandre 7 , Benoit You 8 , Sara Bastian 9 , Matthew G Krebs 10 , Ding Wang 11 , Saiama N Waqar 12 , Mark Lanasa 13 , Joon Rhee 13 , Haiyan Gao 14 , Vidalba Rocher-Ros 14 , Emma V Jones 14 , Sakshi Gulati 14 , Anna Coenen-Stass 14 , Iwanka Kozarewa 14 , Zhongwu Lai 13 , Helen K Angell 14 , Laura Opincar 13 , Pia Herbolsheimer 13 , Bella Kaufman 15
Lancet Oncol . 2020 Sep;21(9):1155-1164. Link
2753. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M Tolaney 1 , Andrew M Wardley 2 , Stefania Zambelli 3 , John F Hilton 4 , Tiffany A Troso-Sandoval 5 , Francesco Ricci 6 , Seock-Ah Im 7 , Sung-Bae Kim 8 , Stephen Rd Johnston 9 , Arlene Chan 10 , Shom Goel 11 , Kristen Catron 12 , Sonya C Chapman 13 , Gregory L Price 12 , Zhengyu Yang 12 , M Corona Gainford 12 , Fabrice André 14
Lancet Oncol . 2020 Jun;21(6):763-775. Link
2752. The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: A prospective observational study
Gyu Han Oh 1 , Chan-Woo Yeom 1 , Eun-Jung Shim 2 , Dooyoung Jung 3 , Kwang-Min Lee 4 , Kyung-Lak Son 5 , Won-Hyoung Kim 6 , Jung Yoon Moon 1 , Sanghyup Jung 1 , Tae-Yong Kim 7 , Seock-Ah Im 8 , Kyung-Hun Lee 7 , Bong-Jin Hahm 9
J Psychosom Res . 2020 Mar;130:109911. Link